Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide

CONCLUSIONS: A high chromosomal instability and neuroendocrine CTC phenotype is independently associated with worse survival in men with mCRPC treated with abi/enza, warranting further prospective controlled predictive studies to inform treatment decisions.PMID:33820782 | DOI:10.1158/1078-0432.CCR-20-3471

Source: Clinical Prostate Cancer - April 6, 2021 Category: Cancer & Oncology Authors: Landon C Brown Susan Halabi Joseph D Schonhoft Qian Yang Jun Luo David M Nanus Paraskevi Giannakakou Russell Z Szmulewitz Daniel C Danila Ethan S Barnett Emily A Carbone Jimmy L Zhao Patrick Healy Monika Anand Audrey Gill Adam Jendrisak William R Berry Sa Source Type: research